Clinical Trial: Irinotecan Liposome Plus Capecitabine and Enronsubemab Combined With Short-course Radiotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cancer

U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07281157) titled 'Irinotecan Liposome Plus Capecitabine and Enronsubemab Combined With Short-course Radiotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cancer' on Dec. 01.

Brief Summary: This is a prospective, single-center, single-arm study on the combination regimen of irinotecan liposome, capecitabine and enronsubemab embedded in short-course radiotherapy as neoadjuvant therapy for locally advanced rectal cancer.

Study Start Date: Jan. 25, 2026

Study Type: INTERVENTIONAL

Condition: Advanced Colorectal Cancer

Intervention: DRUG: Irinotecan Liposome, Capecitabine, and Enlansubemab Plus Short-Course Radiotherapy

Phase One: Induct...